[TAK] Takeda: Q2 FY2026 earnings preview on ENTYVIO, plasma and core profit

Takeda is a Japan-based global biopharmaceutical company whose revenue comes mainly from the gastrointestinal drug ENTYVIO, plasma-derived therapies, rare diseases, oncology and neuroscience[1]. Takeda holds its Q2 FY2026 earnings call on 2026-10-29[2], when it will report FY2026 Q2, the three months ended September 30, 2026. In the latest disclosed quarter, FY2026 Q1 (April to June 2026), revenue was ¥1,219.9 billion, up 10.2% at actual exchange rates because of the weaker yen but down 0.5% at constant exchange rates[3]; core operating profit was ¥358.9 billion, also down 0.5% at constant currency, for a 29.4% core margin[4][5]. Takeda gives only full-year guidance: for FY2026 it guides to a low-single-digit decline in core revenue, a 5%-8% decline in core operating profit and a mid-teens decline in core EPS at constant currency, and at ¥156 per dollar it forecasts revenue of ¥4,640.0 billion and core operating profit of ¥1,160.0 billion[6]. According to analyst estimates compiled by Drillr, the second-quarter revenue consensus is ¥1,155.3 billion from 3 analysts and the EBIT consensus is ¥172.7 billion, a measure closer to reported operating profit than to core operating profit[7]; the full-year revenue consensus of ¥4,688.0 billion from 8 analysts sits slightly above the company's own forecast[8].

Three things matter most in this report. First, can ENTYVIO return to constant-currency growth in the US? It grew 3.8% globally in the first quarter while US sales fell at constant currency[9], which management attributed to pricing mix and fewer days of channel inventory[10]; the US is about two-thirds of ENTYVIO revenue, so a lasting decline would directly widen the full-year revenue gap. Second, can immunoglobulin move from a 0.6% constant-currency decline back to growth while the 66.6% core gross margin holds[11][5]? The company blamed US shipment phasing[12], an explanation that fails if the second quarter is negative again, and plasma products were the main source of the margin improvement. Third, as three new medicines enter launch, can the first-half decline in core operating profit stay clearly smaller than the 5%-8% full-year guidance[6]? Core R&D expense grew 6.8% in the first quarter[4] while transformation savings showed up only modestly[12], so the second quarter will test whether the better-than-guidance start reflects operating resilience or simply the timing of spending.

Company Background and Business Structure

Takeda is a long-established Japanese drugmaker that became global through several large acquisitions[1]. Founded in Osaka in 1781, it acquired Millennium and Nycomed and then bought Shire in 2019, which took it into rare diseases and plasma-derived therapies; its ADSs trade on the New York Stock Exchange, each representing 0.5 of a common share, it reports to the US SEC on Form 20-F, and it employs about 47,000 people worldwide. After the June 2026 shareholders' meeting, Julie Kim succeeded Christophe Weber as president and chief executive officer[13]; in March 2026 the board approved a new transformation program to streamline corporate functions and speed up launches[14].

Takeda has a single operating segment but manages six key business areas, which together produced 95.0% of FY2025 revenue[1]. In FY2025 (ended March 2026), gastroenterology revenue was ¥1,407.5 billion, including ENTYVIO at ¥958.0 billion, GATTEX/REVESTIVE at ¥145.7 billion and TAKECAB at ¥143.7 billion; plasma-derived therapies (PDT) were ¥1,057.5 billion, including immunoglobulin at ¥790.6 billion and albumin at ¥140.3 billion; rare diseases were ¥762.7 billion, including TAKHZYRO at ¥223.9 billion; oncology was ¥580.1 billion; neuroscience was ¥414.3 billion, including VYVANSE at ¥203.2 billion and TRINTELLIX at ¥121.8 billion; and vaccines were ¥59.6 billion, including the dengue vaccine QDENGA at ¥40.8 billion[15]. That means ENTYVIO alone accounts for about a fifth of group revenue, and immunoglobulin plus albumin for roughly another fifth, so these two franchises largely set the direction of the top line.

The US is Takeda's largest market and the one most exposed to policy and pricing[15]. US revenue in FY2025 was ¥2,164.8 billion, down 7.7% at constant currency, mainly because of generic erosion of VYVANSE, while some products were also hit by the Medicare Part D redesign and the expansion of the 340B program; Europe and Canada contributed ¥1,146.2 billion and Japan ¥433.1 billion[15]. In the US, Takeda sells through wholesalers, specialty pharmacies and infusion centers and pays rebates to PBMs, commercial insurers, Medicare and Medicaid, with related rebate provisions of ¥291.2 billion at the end of March 2026[16]; in Japan and other markets, prices are set mainly through reimbursement pricing.

Takeda's operating assets center on its own manufacturing and its plasma collection network[17]. Biologics such as antibodies are made in its own plants and by partners; plasma products rely on more than 270 company-operated donation centers in the US, Austria, Hungary and Czechia plus externally sourced plasma, and take 7-12 months of fractionation and purification to become finished goods[17]. Financially, revenue depends on each product's patient volume and net price after rebates, and plasma products carry the highest unit cost; amortization and impairment of product intangibles, restructuring costs and litigation provisions hit reported profit but not core profit, and operating cash flow is further shaped by rebate payments, receivables factoring and tax timing.

Financial History and Current Position

Takeda's reported profit has swung widely over the past three years, while core operating profit has been steady[18]. For fiscal years ending in March, revenue was ¥4,263.8 billion in FY2023, ¥4,581.6 billion in FY2024 and ¥4,505.7 billion in FY2025; reported operating profit was ¥214.1 billion, ¥342.6 billion and ¥6.2 billion, and net profit attributable to owners was ¥144.1 billion, ¥107.9 billion and a loss of ¥152.4 billion[18]. FY2025 reported profit nearly vanished mainly because of a ¥403.5 billion provision for the AMITIZA antitrust litigation[19]; core operating profit that year was ¥1,172.5 billion, slightly above FY2024's ¥1,162.6 billion and down 0.9% at constant currency[20], and core EPS was ¥517[6].

Cash generation in FY2025 was clearly stronger than the income statement suggests[21]. Operating cash flow was ¥1,041.4 billion, free cash flow ¥865.4 billion and adjusted free cash flow ¥684.5 billion, down ¥84.4 billion from the prior year mainly because of higher cash spent on intangible assets[21], including a ¥184.7 billion upfront payment to Innovent Biologics[6].

The weaker yen visibly inflated the reported figures for FY2026 Q1 (April to June 2026)[3]. Revenue was ¥1,219.9 billion, up 10.2% at actual rates, with currency adding ¥118.2 billion[12], but down 0.5% at constant currency; reported operating profit was ¥201.4 billion and net profit attributable to owners ¥113.2 billion[3]. Core operating profit was ¥358.9 billion, for a 29.4% core margin, and core EPS was ¥154[5]. By business area, gastroenterology grew 3.1% at constant currency and oncology 8.2%, while rare diseases fell 5.8%, PDT 2.1% and neuroscience 4.8%; by region, US revenue was ¥568.9 billion, down 5.2% at constant currency[22].

First-quarter cash flow was much weaker than a year earlier, though balance-sheet leverage remains moderate[23]. Operating cash flow was ¥127.6 billion against ¥215.4 billion a year earlier, a decline driven mainly by higher receivables[23], which management attributed to changes in its receivables factoring program[12]; adjusted free cash flow was ¥68.6 billion against ¥190.1 billion[24] and included a $200 million payment to Protagonist[12]. At the end of June, cash stood at ¥461.0 billion and bonds and loans at ¥4,940.0 billion[25], and adjusted net debt to adjusted EBITDA was 2.7 times[26].

With its first-quarter results, Takeda kept the FY2026 forecast it published in May[6]. Assuming ¥156 per dollar, the company forecasts revenue of ¥4,640.0 billion, core operating profit of ¥1,160.0 billion, reported operating profit of ¥420.0 billion and net profit attributable to owners of ¥166.0 billion, alongside assumptions of ¥170.0 billion in restructuring costs, ¥650.0 billion to ¥750.0 billion in adjusted free cash flow and ¥330.0 billion to ¥380.0 billion in capital expenditure[6]; the planned annual dividend is ¥204 per share.

Operating Model

Takeda's revenue can be read as each product's patient volume times its realized net price after rebates, plus or minus changes in channel inventory[15]. From FY2026 the company manages its products in three groups: Core In-line Brands (ENTYVIO, GATTEX, TAKECAB, TAKHZYRO, immunoglobulin, albumin and ADCETRIS), New Launches (medicines within five years of launch) and products facing loss of exclusivity or in maturity[27]. In the first quarter, Core In-line Brands were 58% of core revenue and grew 2.3% at constant currency, while New Launches were 4% and grew 22.6%, and together their growth was largely offset by declines in off-patent products[4]. Near-term revenue direction therefore turns on two things: whether Core In-line Brands sustain low-single-digit growth, and how fast products such as VYVANSE and TRINTELLIX erode.

Core operating profit equals core revenue minus core cost of sales, core SG&A and core R&D, and reported operating profit then subtracts amortization and impairment of product intangibles and adds or subtracts other operating items such as restructuring, litigation and divestitures[4]. In the first quarter, core revenue of ¥1,219.9 billion less core cost of sales of ¥407.0 billion left core gross profit of ¥812.9 billion, a 66.6% margin; after core SG&A of ¥286.6 billion and core R&D of ¥167.4 billion, core operating profit was ¥358.9 billion[5]. Moving from core to reported profit, the quarter also absorbed ¥110.9 billion of product-intangible amortization and impairment and ¥55.2 billion of other operating expenses, within which restructuring costs rose ¥35.8 billion year on year[28]. This structure means gross-margin changes pass through to core gross profit scaled by revenue, while launch spending and R&D reduce core profit in the quarter they are recognized.

Cash flow starts from operating profit plus amortization, less working capital and taxes, and then less capital expenditure and purchases of intangibles[24]. In the first quarter, a ¥127.3 billion increase in trade working capital was the main reason operating cash flow fell, while purchases of property, plant and equipment were ¥53.8 billion and purchases of intangibles ¥49.4 billion[24]. Cash goes mainly to dividends and debt service, and if the AMITIZA case ultimately requires payment, cash would fall directly and leverage would rise[19]. The gap between profit and cash is therefore set mainly by working-capital timing: shifts in rebates, factoring and inventory appear first in working capital and only later in full-year adjusted free cash flow.

The three key drivers differ in direction and lag. Changes in ENTYVIO's US net price and inventory days show up in revenue in the same quarter, while patient conversion to the subcutaneous pen builds quarter by quarter[29]; plasma collected needs 7-12 months of fractionation and purification before it becomes saleable immunoglobulin, so gains in collection and manufacturing efficiency reach supply and gross margin with a delay[17]; launch costs and late-stage R&D are expensed as incurred, while many transformation measures only took effect at the end of the first quarter[12], and the timing gap between the two determines how full-year core profit is spread across quarters.

Industry and Competitive Position

By revenue, Takeda is Japan's largest drugmaker and one of the world's main suppliers of plasma-derived therapies, where peers include CSL and Grifols. Its competitive strengths lie in two places: ENTYVIO remains the most prescribed brand in inflammatory bowel disease and leads in first-line ulcerative colitis[10], and its plasma supply rests on a network of more than 270 company-run donation centers[17].

The inflammatory bowel disease market in which ENTYVIO competes is crowded[30]. The annual report lists principal competitors including Remicade and Stelara from Johnson & Johnson's Janssen, Tremfya from Johnson & Johnson, Humira, Rinvoq and Skyrizi from AbbVie, Xeljanz and Velsipity from Pfizer, Omvoh from Eli Lilly, Zeposia from BMS, and biosimilars of infliximab, adalimumab and ustekinumab[30]. Some of ENTYVIO's formulation, dosing-regimen and manufacturing patents expire in 2032, and biosimilars seeking to launch before then must challenge all relevant patents, so the exact timing of entry is uncertain[29]; on the first-quarter call, management said litigation should still take roughly three to five years and that the overall timeline is unchanged[31].

Takeda's main weakness is that several mature products are losing exclusivity at once[32]. VYVANSE was heavily replaced by generics after its US composition-of-matter patent expired in August 2023, with revenue falling from ¥350.6 billion in FY2024 to ¥203.2 billion in FY2025, and certain TRINTELLIX exclusivity ends in December 2026[32]; in rare diseases, TAKHZYRO also fell 2.2% at constant currency in the first quarter because of stronger US competition[33]. The offset comes from new medicines: ORZEYFUL, the first orexin receptor 2 agonist, won FDA approval for narcolepsy type 1 on August 5, 2026[13]; the hepcidin mimetic MIMRYLO was approved for polycythemia vera on August 28[34]; and the psoriasis application for the oral TYK2 inhibitor zasocitinib received Priority Review, with a PDUFA date in the first quarter of 2027[35].

These comparisons have clear limits. Takeda does not disclose prescription volumes, unit prices, channel inventory days or plasma collection volumes, so volume-and-price comparisons with competitors rest on management's qualitative statements; ENTYVIO's constant-currency US growth rate also appears only on the earnings call, not in the quarterly filing[10].

Core Debates

ENTYVIO grew 3.8% globally at constant exchange rates in the first quarter, but its US sales declined, which Takeda attributed to pricing mix and lower channel inventory. Can US sales return to growth in the second quarter?

This question matters because ENTYVIO is about a fifth of Takeda's revenue and the US is about two-thirds of ENTYVIO[15][29]. The full-year guidance for lower core revenue and a 5%-8% decline in core operating profit[6] assumes, among other things, that Core In-line Brands such as ENTYVIO keep growing, and in the first quarter that group was 58% of core revenue and grew 2.3%[4]. If the largest product's US decline is not temporary, the revenue gap will widen while the three new medicines are still early in launch.

First-quarter evidence shows ENTYVIO's growth came mainly from outside the US[9]. ENTYVIO revenue was ¥268.3 billion, up 3.8% at constant currency; US revenue was ¥169.5 billion, up 8.4% at actual rates, mainly because of the weaker yen[9]. Management said US sales fell at constant currency because of pricing mix and lower days on hand, while overall demand was still growing and the ENTYVIO pen was growing strongly in the US; Europe grew about 6.7%, Japan about 10% and other international markets about 36%[10]. For comparison, ENTYVIO grew 4.2% in FY2025, and US sales rose only 0.7% at actual rates[29].

The financial chain runs like this: US patients on therapy (including conversion to the subcutaneous pen) times realized net price (rebates, the Medicare Part D redesign and pricing mix), plus or minus wholesaler inventory days, sets ENTYVIO revenue, which in turn drives gastroenterology revenue and core gross profit. The alternative reading is that US net price keeps falling under the Medicare Part D redesign and competition from oral IBD drugs, and that inventory days merely amplified one quarter's decline[15]; if US sales fall again in the second quarter while inventory days have stabilized, that reading gains weight. On patents, the 2032 timeline is unchanged, and management expects biosimilar litigation to take another three to five years[31].

In the second-quarter report, watch whether first-half ENTYVIO growth at constant currency is at least 3.8%, whether US sales return to constant-currency growth and management still cites inventory days, whether Europe holds above 6%, and how management describes US demand and pen share. If first-half global growth falls below 2%, US price pressure has outrun subcutaneous volume gains; if management attributes the US decline to demand or share, the inventory explanation no longer holds.

Immunoglobulin is Takeda's second-largest franchise, yet it slipped slightly at constant exchange rates in the first quarter, which management called US shipment phasing. Can it return to growth in the second quarter while gross margin holds?

Immunoglobulin and albumin together are about a fifth of Takeda's revenue and the bulk of its Core In-line Brands[15]. Plasma products carry high unit costs, so their growth and cost efficiency set both revenue and core gross margin; after the loss of high-margin products such as VYVANSE pushed the cost ratio up through product mix, PDT cost improvement is the key to holding gross margin[20].

First-quarter immunoglobulin revenue was ¥213.9 billion, down 0.6% at constant currency, with the subcutaneous products CUVITRU and HYQVIA growing by double digits while the intravenous GAMMAGARD LIQUID/KIOVIG rose slightly only because of currency; albumin revenue was ¥34.6 billion, down 5.0% at constant currency[11]. The CFO said both were affected by US phasing, within the company's expectations[12]. Over the same period, inventories rose ¥50.6 billion from the end of March, mainly work in process for PDT products and ENTYVIO[25]; the core gross margin was 66.6%, up 1.4 percentage points year on year[5], and the CFO said the improvement came mainly from PDT products[36]. As an annual reference, immunoglobulin grew 4.1% in FY2025 and albumin fell 2.1%[17][15], and the core gross margin derived from core revenue and core cost of sales was about 65.1%[20].

The financial chain runs like this: plasma collection and plant output determine how much immunoglobulin is available, which times realized price, plus or minus US shipment phasing, produces PDT revenue of roughly 23% of the group, while PDT unit cost in turn drives core gross margin. In FY2025, Takeda rolled out personalized collection protocols across its more than 270 centers and collection volume kept growing[17]. The alternative reading is that US intravenous immunoglobulin faces new-therapy competition and price pressure in indications such as CIDP (chronic inflammatory demyelinating polyneuropathy), and that the first-quarter decline marks the start of slower demand; a negative first half overall with subcutaneous products still growing by double digits would support that reading.

In the second-quarter report, watch whether first-half immunoglobulin growth turns positive at constant currency, whether albumin's decline narrows, whether subcutaneous products keep double-digit growth, whether inventories come down, and whether core gross margin stays at or above 66%. If first-half immunoglobulin is still negative, the phasing explanation fails; if core gross margin drops below 65%, the first-quarter cost improvement is not sustainable.

Takeda guides for a 5%-8% decline in core operating profit this fiscal year, yet the first quarter fell only 0.5%. With three new medicines now drawing launch spending, can first-half profit stay at the better end of that range?

Takeda frames FY2026 as its "first phase": generic erosion pushes core revenue down while the company steps up spending on three launches and its late-stage pipeline, funded by the transformation program launched in March 2026, which is expected to generate ¥170 billion of restructuring costs this year[14]. Core operating profit is the company's guidance metric, and where first-half profit lands within the range will shape how credible outsiders find the plan to fund growth with savings[12].

In the first quarter, core revenue of ¥1,219.9 billion and core operating profit of ¥358.9 billion both fell 0.5% at constant currency, better than full-year guidance; core R&D expense rose 6.8%[4], the CFO said savings were limited because many measures took effect at quarter-end[12], and restructuring costs rose ¥35.8 billion year on year[28]. VYVANSE's decline narrowed from 43.0% in FY2025 to 17.0% in the first quarter[37][15]; New Launches were 4% of core revenue and grew 22.6%[4]. ORZEYFUL and MIMRYLO won FDA approval in August[13][34], and zasocitinib has a PDUFA date in the first quarter of 2027[35].

The financial chain runs like this: erosion of off-patent products such as VYVANSE and TRINTELLIX depresses core revenue, while higher selling costs for launches and higher late-stage R&D, offset against transformation savings, set core SG&A, R&D and ultimately core operating profit. The alternative reading is that the better-than-guidance first quarter only reflects the timing of spending: subtracting first-quarter actuals from the company's full-year forecast implies a core margin of about 23% for the remaining three quarters, below the first quarter's 29.4%[6], which is arithmetic rather than company guidance; launch costs and generic competition for TRINTELLIX from December will both concentrate in the second half[32]. If the first-half decline is already near 5%, profit pressure is arriving faster than savings.

In the second-quarter report, watch whether the first-half decline in core operating profit at constant currency is smaller than 3%, whether full-year guidance is maintained, how fast core R&D and SG&A grow, whether ORZEYFUL completes US Drug Enforcement Administration (DEA) scheduling and launches[13], early patient numbers and payer coverage, and whether VYVANSE's decline keeps narrowing; management has said it will track metrics such as patient numbers, payer coverage and source of patients early in launch[38]. A first-half decline in core operating profit of 5% would mean savings are not keeping pace with spending; a guidance cut would mean revenue erosion or launch spending has exceeded plan.

Risks and Falsifiers

The AMITIZA antitrust case is the largest single risk to cash and leverage[19]. In May 2026, a jury awarded about $885 million in single damages, with the wholesaler and retailer portions automatically trebled on entry of judgment; Takeda has booked a ¥403.5 billion provision, which cut FY2025 reported operating profit to ¥6.2 billion[18], and plans to appeal and seek a stay of execution. If payment is ultimately required, it would hit the full-year adjusted free cash flow guidance of ¥650.0 billion to ¥750.0 billion[6] and the 2.7 times adjusted net debt to adjusted EBITDA at the end of the first quarter[26]. If the court grants a stay or no payment is due during the appeal, and the provision does not grow in the second quarter, the risk will not turn into a cash outflow in the near term.

Currency and working capital pull reported figures away from the underlying business[12]. The weaker yen added ¥118.2 billion to first-quarter revenue, and the full-year forecast assumes ¥156 per dollar[6]; meanwhile, changes in the receivables factoring program cut first-quarter operating cash flow to ¥127.6 billion and adjusted free cash flow to just ¥68.6 billion, against ¥190.1 billion a year earlier[24]. Reported revenue and profit are exposed, as are the full-year adjusted free cash flow guidance and the planned ¥204 per-share dividend. If first-half adjusted free cash flow returns to a pace consistent with full-year guidance, roughly ¥300 billion or more, and the company keeps its cash flow guidance, this concern does not hold.

A sustained decline in US ENTYVIO net price is the largest revenue-side risk[10]. The Medicare Part D redesign, PBM rebates and competition from oral and new-mechanism IBD drugs can push realized prices down faster than subcutaneous volume gains can offset[30]; the exposure is US ENTYVIO revenue of ¥623.7 billion in FY2025, about 14% of the group, along with gastroenterology gross profit[29]. If US ENTYVIO returns to constant-currency growth in the first half and management confirms demand is growing, this risk is falsified.

Weaker demand or pricing for intravenous immunoglobulin would hit revenue and gross margin at the same time[11]. Sources of this risk include new-mechanism therapies in US indications such as CIDP, the effects of the Medicare Part D redesign, or collection and manufacturing disruptions that constrain supply; the exposure is PDT revenue of ¥1,057.5 billion in FY2025, about 23% of the group, and core gross margin[15]. If immunoglobulin returns to positive constant-currency growth in the first half and inventories come down[25], this risk does not hold.

Faster loss of exclusivity combined with launch spending is the most direct risk to core profit[32]. Certain TRINTELLIX exclusivity ends in December 2026 on a product that generated ¥121.8 billion in FY2025, VYVANSE is still declining, and launch costs for three new medicines are front-loaded while transformation savings arrive later[12]; the exposure is FY2025 core operating profit of ¥1,172.5 billion and full-year guidance for a 5%-8% decline at constant currency[6]. If the first-half decline in core operating profit at constant currency is smaller than 3% and full-year guidance is maintained, this risk has not materialized.

What to Watch Next

• US ENTYVIO: first-quarter US sales were ¥169.5 billion and, per management, down at constant currency. A return to growth with confirmed demand supports the inventory explanation; attributing the decline to demand or share undermines it.
• Global ENTYVIO: first-quarter growth was 3.8%, with Europe at about 6.7%. First-half growth below 2% would mean US price pressure has outrun pen volume.
• Immunoglobulin and albumin: first-quarter growth was −0.6% and −5.0% at constant currency. A negative first half would invalidate the phasing explanation.
• Gross margin and inventory: the first-quarter core gross margin was 66.6% and inventory rose ¥50.6 billion from March. A margin below 65% would show the cost improvement is not sustainable.
• Core operating profit: the first quarter fell 0.5% against full-year guidance of −5% to −8%. A first-half decline reaching 5%, or a guidance cut, would show savings lagging spending.
• Launches: ORZEYFUL scheduling and launch, and early MIMRYLO patients, payer coverage and patient sources. Delays or slow coverage would amplify the cost of front-loaded spending.
• Cash and litigation: first-quarter adjusted free cash flow was ¥68.6 billion and the AMITIZA provision ¥403.5 billion. Reaching roughly ¥300 billion in the first half with a stay granted would ease the cash concern.

Conclusion

Three forces drive Takeda's business: ENTYVIO and plasma-derived therapies, each about a fifth of revenue; generic erosion of products such as VYVANSE and TRINTELLIX; and launch spending for three new medicines set against transformation savings. In the first quarter, core revenue and core operating profit each fell only 0.5% at constant currency and core gross margin rose to 66.6%[5], better than the full-year guidance for a 5%-8% decline in core operating profit[6]; but adjusted free cash flow was only ¥68.6 billion, and the ¥403.5 billion AMITIZA provision remains unresolved[19]. The central open question is whether the first-quarter dips in US ENTYVIO and immunoglobulin reflect inventory and shipment timing or lasting price and demand pressure, and whether savings can keep pace with launch spending.

Since the first-quarter results, the outside material available has mainly been news coverage of the ORZEYFUL and MIMRYLO approvals and the zasocitinib filing acceptance, plus summaries of the call held before the annual report, and none of it offers an independent judgment on these debates that can be checked against its original text. There is therefore no outside interpretation to synthesize, and no citable outside view has formed. Readers currently have only the company's own disclosures and management's statements, and the latter should be read as the company's position rather than independent judgment.

From here, if first-half US ENTYVIO returns to constant-currency growth, immunoglobulin turns positive with core gross margin at 66% or higher, the core operating profit decline stays below 3%, adjusted free cash flow reaches roughly ¥300 billion, and the AMITIZA judgment is stayed, both the inventory-and-phasing explanation and the savings-fund-growth path would be materially strengthened. Conversely, if US ENTYVIO keeps falling after inventory has stabilized, immunoglobulin stays negative, core gross margin drops below 65%, the first-half core profit decline nears 5% or the company cuts guidance, the current understanding would be materially weakened.

Sources

[1] TAK 20-F filed 2026-06-17 · business overview and key business areas · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[2] Drillr earnings calendar (updated 2026-10-18) · TAK 2026-10-29 call · 2026-10-18 · Drillr earnings calendar · https://gateway.drillr.ai/mcp/private

[3] TAK 6-K filed 2026-07-30 · FY2026 Q1 consolidated results · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[4] TAK 6-K filed 2026-07-30 · FY2026 Q1 core results and product categories · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[5] TAK 6-K filed 2026-07-30 · Financial Appendix FY2026 Q1 core results with gross margin · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/exhibit991_073026.htm

[6] TAK 6-K filed 2026-07-30 · FY2026 forecast, assumptions and management guidance · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[7] Drillr analyst_financial_estimates (updated 2026-10-16) · TAK quarter ending 2026-09-30 · 2026-10-16 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[8] Drillr analyst_financial_estimates (updated 2026-10-16) · TAK FY2026 (ending 2027-03-31) · 2026-10-16 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[9] TAK 6-K filed 2026-07-30 · FY2026 Q1 ENTYVIO and GI · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[10] TAK FY2026 Q1 earnings call 2026-07-30 · ENTYVIO US demand and pricing · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[11] TAK 6-K filed 2026-07-30 · FY2026 Q1 PDT immunoglobulin and albumin · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[12] TAK FY2026 Q1 earnings call 2026-07-30 · CFO revenue, profit and cash bridge · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[13] TAK 6-K filed 2026-08-05 · FDA approval of ORZEYFUL (oveporexton) · 2026-08-05 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000329/form6k_080526.htm

[14] TAK 20-F filed 2026-06-17 · efficiency program and FY2026 restructuring · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[15] TAK 20-F filed 2026-06-17 · FY2025 revenue by region and business area · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[16] TAK 20-F filed 2026-06-17 · US rebate provisions · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[17] TAK 20-F filed 2026-06-17 · plasma collection network and immunoglobulin sales · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[18] TAK 20-F filed 2026-06-17 · consolidated results FY2023-FY2025 · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[19] TAK 20-F filed 2026-06-17 · AMITIZA antitrust verdict and provision · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[20] TAK 20-F filed 2026-06-17 · FY2025 core revenue and core operating profit · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[21] TAK 20-F filed 2026-06-17 · FY2025 operating cash flow and free cash flow · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[22] TAK 6-K filed 2026-07-30 · FY2026 Q1 revenue by region and business area · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[23] TAK 6-K filed 2026-07-30 · FY2026 Q1 cash flows · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[24] TAK 6-K filed 2026-07-30 · Financial Appendix FY2026 Q1 adjusted free cash flow · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/exhibit991_073026.htm

[25] TAK 6-K filed 2026-07-30 · FY2026 Q1 financial position, receivables and inventories · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[26] TAK 6-K filed 2026-07-30 · Financial Appendix adjusted net debt to adjusted EBITDA · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/exhibit991_073026.htm

[27] TAK 20-F filed 2026-06-17 · New Launches and Core In-line Brands categories · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[28] TAK 6-K filed 2026-07-30 · FY2026 Q1 costs, amortization and restructuring · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[29] TAK 20-F filed 2026-06-17 · ENTYVIO sales, subcutaneous formulation and 2032 patents · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[30] TAK 20-F filed 2026-06-17 · principal competing products for ENTYVIO · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[31] TAK FY2026 Q1 earnings call 2026-07-30 · ENTYVIO biosimilar timeline · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[32] TAK 20-F filed 2026-06-17 · VYVANSE generic erosion and TRINTELLIX exclusivity · 2026-06-17 · 20-F · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm

[33] TAK 6-K filed 2026-07-30 · FY2026 Q1 Rare Diseases · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[34] TAK 6-K filed 2026-08-28 · FDA approval of MIMRYLO (rusfertide) · 2026-08-28 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000331/form6k_082826.htm

[35] TAK 6-K filed 2026-09-14 · zasocitinib NDA accepted under Priority Review · 2026-09-14 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000337/form6k_091426.htm

[36] TAK FY2026 Q1 earnings call 2026-07-30 · gross margin drivers · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[37] TAK 6-K filed 2026-07-30 · FY2026 Q1 Oncology, Vaccines and Neuroscience · 2026-07-30 · 6-K · https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm

[38] TAK FY2026 Q1 earnings call 2026-07-30 · launch readiness and launch metrics · 2026-07-30 · earnings-call · https://gateway.drillr.ai/mcp/private